Belite Bio reports Q2 loss, FDA accepts tinlarebant NDA
Belite Bio said the FDA accepted its new drug application for tinlarebant with priority review and set a PDUFA date of February 12, 2027, while Q2 GAAP net loss widened to $28.4 million from $16.3 million.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.